Floatz logo

Ari-0001

Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Ruijin HospitalCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Relapsed/Refractory Large B-cell Lymphoma (LBCL) cohort.

Asset / SponsorPhaseRating
Rimegepant
Ruijin Hospital
Phase 2CCC
Firi-Cel
CARGO Therapeutics
Phase 2CCC

Same molecule, other indications

Ari-0001 is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
Acute Lymphoblastic Leukemia ,LymphomasDormant
B
Indicative ·
60 / 100
View asset →
Primary Mediastinal B-cell Lymphoma (PMBCL)Dormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →